Detalles de la búsqueda
1.
Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Prostate
; 77(10): 1137-1143, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28543353
2.
Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
BJU Int
; 120(4): 511-519, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28267899
3.
Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.
Qual Life Res
; 26(6): 1635-1645, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28168601
4.
Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
Int J Urol
; 24(4): 281-286, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28173626
5.
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
BJU Int
; 118(3): 366-71, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26765682
6.
Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.
World J Urol
; 34(2): 253-60, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160006
7.
Ethnicity and prostate cancer: the way to solve the screening problem?
BMC Med
; 13: 179, 2015 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26239718
8.
Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
J Urol
; 194(2): 336-42, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25698407
9.
Overall survival benefit of androgen suppression in addition to dose-escalated external beam radiotherapy for high-risk prostate cancer: Nationwide real-world data indicates a shift in men that benefit.
Urol Oncol
; 42(8): 245.e9-245.e18, 2024 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724349
10.
Active surveillance: oncologic outcome.
Curr Opin Urol
; 23(3): 268-72, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23425994
11.
Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator.
Transl Androl Urol
; 12(2): 241-248, 2023 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36915892
12.
Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
BJU Int
; 110(11): 1654-60, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23043563
13.
Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
BJU Int
; 118(5): 677-680, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27104278
14.
The ProtecT trial: what can we expect?
Lancet Oncol
; 15(10): 1046-7, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25163904
15.
Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Eur Urol Focus
; 5(3): 407-415, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29331622
16.
Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?
Eur Urol
; 73(3): 343-350, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28647216
17.
Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.
Eur Urol
; 82(4): 441, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902289
18.
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Eur Urol
; 70(6): 954-960, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27329565
19.
Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Eur Urol
; 69(6): 1129-34, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26651990
20.
Active surveillance for prostate cancer: a narrative review of clinical guidelines.
Nat Rev Urol
; 13(3): 151-67, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26813955